Citadel Downgrades Savient Pharmaceuticals To Neutral, $9 PT

May 20, 2011 6:17 AM | 7 seconds read |
Citadel Securities has downgraded Savient Pharmaceuticals SVNT from Buy to Neutral and has established a $9 price target.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: DowngradesPrice TargetAnalyst RatingsBiotechnologycitadelHealth Caresavient pharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!